

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kinnevik AB (publ)</u>			2. Issuer Name and Ticker or Trading Symbol <u>Livongo Health, Inc. [ LVGO ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) <input type="checkbox"/> Other (specify below) <input type="checkbox"/>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>07/29/2019</u>			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input type="checkbox"/> <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
SKEPPSBRON 18, P.O. BOX 2094			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) STOCKHOLM V7 SE-103 13								
(City) (State) (Zip)								

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common stock, \$0.001 par value per share	07/29/2019		C <sup>(1)</sup>		18,771	A	(1)	1,699,974	I	See footnote <sup>(2)</sup>
Common stock, \$0.001 par value per share	07/29/2019		C <sup>(3)</sup>		11,268	A	(3)	1,711,242	I	See footnote <sup>(2)</sup>
Common stock, \$0.001 par value per share	07/29/2019		C <sup>(4)</sup>		2,816,790	A	(4)	4,528,032	I	See footnote <sup>(2)</sup>
Common stock, \$0.001 par value per share	07/29/2019		C <sup>(5)</sup>		4,984,100	A	(5)	9,512,132	I	See footnote <sup>(2)</sup>
Common stock, \$0.001 par value per share	07/29/2019		P <sup>(7)</sup>		2,991,795	A	\$28	12,503,927	I	See footnote <sup>(2)</sup>
Common stock, \$0.001 par value per share	07/29/2019		P <sup>(8)</sup>		150,000	A	\$28	12,653,927	I	See footnote <sup>(2)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A convertible preferred stock	(1)	07/29/2019		C		18,771		(1)	(1)	Common stock, \$0.001 par value per share	18,771	\$0 <sup>(1)</sup>	0	I	See footnote <sup>(6)</sup>
Series C convertible preferred stock	(3)	07/29/2019		C		11,268		(3)	(3)	Common stock, \$0.001 par value per share	11,268	\$0 <sup>(3)</sup>	0	I	See footnote <sup>(6)</sup>
Series D convertible preferred stock	(4)	07/29/2019		C		2,816,790		(4)	(4)	Common stock, \$0.001 par value per share	2,816,790	\$0 <sup>(4)</sup>	0	I	See footnote <sup>(6)</sup>
Series E convertible preferred stock	(5)	07/29/2019		C		4,984,100		(5)	(5)	Common stock, \$0.001 par value per share	4,984,100	\$0 <sup>(5)</sup>	0	I	See footnote <sup>(6)</sup>

1. Name and Address of Reporting Person\*  
Kinnevik AB (publ)

(Last) (First) (Middle)  
SKEPPSBRON 18, P.O. BOX 2094

(Street)  
STOCKHOLM V7 SE-103 13

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Kinnevik Online AB</a>		
(Last)	(First)	(Middle)
SKEPPSBRON 18, P.O. BOX 2094		
(Street)		
STOCKHOLM	V7	SE-103 13
(City)		
(State)	(Zip)	

**Explanation of Responses:**

- Each share of Series A convertible preferred stock automatically converted into the Issuer's common stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering (the "IPO"), which closed on July 29, 2019, for no additional consideration. The shares had no expiration date.
- The shares of common stock are directly beneficially owned by Kinnevik Online AB ("Kinnevik Online"). Kinnevik AB (publ), as the sole shareholder of Kinnevik Online, may be deemed to have shared voting and dispositive power, and therefore, beneficial ownership, over the shares of common stock owned directly by Kinnevik Online.
- Each share of Series C convertible preferred stock automatically converted into the Issuer's common stock on a 1:1 basis immediately prior to the closing of the Issuer's IPO, which closed on July 29, 2019, for no additional consideration. The shares had no expiration date.
- Each share of Series D convertible preferred stock automatically converted into the Issuer's common stock on a 1:1 basis immediately prior to the closing of the Issuer's IPO, which closed on July 29, 2019, for no additional consideration. The shares had no expiration date.
- Each share of Series E convertible preferred stock automatically converted into the Issuer's common stock on a 1:1 basis immediately prior to the closing of the Issuer's IPO, which closed on July 29, 2019, for no additional consideration. The shares had no expiration date.
- The shares of Series A convertible preferred stock, Series C convertible preferred stock, Series D convertible preferred stock and Series E convertible preferred stock (collectively, the "Preferred Stock") were directly beneficially owned by Kinnevik Online. Kinnevik AB (publ), as the sole shareholder of Kinnevik Online, was deemed to have shared voting and dispositive power, and therefore, beneficial ownership, over the shares of Preferred Stock owned directly by Kinnevik Online.
- Concurrently with the IPO, on July 29, 2019, pursuant to a stock transfer agreement with Merck Global Health Innovation Fund, LLC ("Merck") and other parties thereto, dated July 15, 2019, Kinnevik Online purchased from Merck 2,991,795 shares of common stock in a secondary private placement at the IPO price of \$28.00 per share.
- In connection with the Issuer's IPO, on July 29, 2019, Kinnevik Online purchased an aggregate of 150,000 shares of common stock at the IPO price of \$28.00 per share.

[/s/ Mattias Andersson, as  
authorized signatory of  
Kinnevik AB \(publ\)](#) [07/31/2019](#)

[/s/ Torun Litzen, as authorized  
signatory of Kinnevik Online  
AB](#) [07/31/2019](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**